Pancreatic ductal adenocarcinoma
![VCN-01 Plus Chemotherapy Receives FDA Orphan Drug Designation for Early PDAC Treatment - Pharmtales - Latest Pharma News & Analysis](https://pharmtales.com/wp-content/uploads/2023/06/VCN-01-Plus-Chemotherapy-Receives-FDA-Orphan-Drug-Designation-for-Early-PDAC-Treatment-Pharmtales-Latest-Pharma-News-Analysis.jpg)
VCN-01 Plus Chemotherapy Receives FDA Orphan Drug Designation for Early PDAC Treatment
SG Tylor
Source – Theriva Biologics On 28June 2023, the FDA has granted Orphan Drug Designation (ODD) to VCN-01 in combination with ...
![Combining mitazalimab with chemotherapy demonstrates significant antitumor activity in metastatic pancreatic ductal adenocarcinoma _ Pharmtales - Latest Pharma News & Insights](https://pharmtales.com/wp-content/uploads/2023/06/Combining-mitazalimab-with-chemotherapy-demonstrates-significant-antitumor-activity-in-metastatic-pancreatic-ductal-adenocarcinoma-_-Pharmtales-Latest-Pharma-News-Insights.jpg)
Combining mitazalimab with chemotherapy demonstrates significant antitumor activity in metastatic pancreatic ductal adenocarcinoma
SG Tylor
Source – Alligator Bioscience On June 26, 2023 the combination of mitazalimab, a novel CD40 monoclonal antibody agonist, with chemotherapy ...